SS&C GlobeOp Forward Redemption Indicator

WINDSOR, Conn.--(BUSINESS WIRE)--May 21, 2025--

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the SS&C GlobeOp Forward Redemption Indicator for May 2025 measured 2.34%, up from 1.85% in April.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521488083/en/

“SS&C GlobeOp’s Forward Redemption Indicator for May 2025 was 2.34%. The figure represents a decrease in termination notices compared to the 2.78% reported for the same period a year ago,” said Bill Stone, Chairman and Chief Executive Officer, SS&C Technologies. “Recent favorable trends in asset retention indicate investors favor the strong risk-adjusted and uncorrelated returns provided by hedge funds. These returns help investors mitigate the recent bouts of volatility in both equity and fixed income markets.”

The SS&C GlobeOp Forward Redemption Indicator represents the sum of forward redemption notices received from investors in hedge funds administered by SS&C GlobeOp on the SS&C GlobeOp platform, divided by the AuA at the beginning of the month for SS&C GlobeOp fund administration clients on the SS&C GlobeOp platform. Forward redemptions as a percentage of SS&C GlobeOp's assets under administration on the SS&C GlobeOp platform have trended significantly lower since reaching a high of 19.27% in November 2008. The next publication date is June 23, 2025.

Published on the 15th business day of the month, the SS&C GlobeOp Forward Redemption Indicator presents a timely and accurate view of the redemption pipeline for investors in hedge funds on the SS&C GlobeOp administration platform. Movements in the Indicator reflect investor confidence in their allocations to hedge funds. Indicator data is based on actual investor redemption notifications received. Unlike subscriptions, redemption notifications are typically received 30-90 days in advance of the redemption date. Investors may, and sometimes do, cancel redemption notices. In addition, the establishment and enforcement of redemption notices may vary from fund to fund.

SS&C GlobeOp Hedge Fund Performance Index

SS&C GlobeOp Capital Movement Index

SS&C GlobeOp Forward Redemption Indicator

About the SS&C GlobeOp Hedge Fund Index®

The SS&C GlobeOp Hedge Fund Index (the Index) is a family of indices published by SS&C GlobeOp. A unique set of indices by a hedge fund administrator, it offers clients, investors and the overall market a welcome transparency on liquidity, investor sentiment and performance. The Index is based on a significant platform of diverse and representative assets.

The SS&C GlobeOp Capital Movement Index and the SS&C GlobeOp Forward Redemption Indicator provide monthly reports based on actual and anticipated capital movement data independently collected from all hedge fund clients for whom SS&C GlobeOp provides administration services on the SS&C GlobeOp platform.

The SS&C GlobeOp Hedge Fund Performance Index is an asset-weighted benchmark of the aggregate performance of funds for which SS&C GlobeOp provides monthly administration services on the SS&C GlobeOp platform. Flash estimate, interim and final values are provided, in each of three months respectively, following each business month-end.

While individual fund data is anonymized by aggregation, the SS&C GlobeOp Hedge Fund Index data will be based on the same reconciled fund data that SS&C GlobeOp uses to produce fund net asset values (NAV). Funds acquired through the acquisition of Citi Alternative Investor Services are integrated into the index suite starting with the January 2017 reporting periods. SS&C GlobeOp’s total assets under administration on the SS&C GlobeOp platform represent approximately 10% of the estimated assets currently invested in the hedge fund sector. The investment strategies of the funds in the indices span a representative industry sample. Data for middle and back office clients who are not fund administration clients is not included in the Index, but is included in the Company’s results announcement figures.

About SS&C Technologies

SS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices around the world. More than 22,000 financial services and healthcare organizations, from the world's largest companies to small and mid-market firms, rely on SS&C for expertise, scale and technology.

Additional information about SS&C (Nasdaq: SSNC) is available at www.ssctech.com.

Follow SS&C on X, LinkedIn and Facebook.

SS&C GlobeOp Forward Redemption Indicator

LONDON (AP) — King Charles III has been “deeply touched” by the response to his update on his cancer treatment, Buckingham Palace said Saturday, adding that the monarch is pleased to have highlighted the value of screening programs for the disease.

Medics and health charities have praised the king for his openness, saying his statement on Friday had already prompted people to seek information about cancer.

In a strikingly personal video statement, the British monarch acknowledged that a cancer diagnosis can feel “overwhelming,” but said catching the disease early brings “the precious gift of hope.”

Here’s what to know about the king's condition and his message.

The 77-year-old king said in a statement broadcast Friday that his treatment schedule will be reduced in the new year, “thanks to early diagnosis, effective intervention and adherence to ‘doctors’ orders.’”

He encouraged others to take advantage of screening programs such as those for breast, bowel and cervical cancer offered by Britain’s public health service.

“Early diagnosis quite simply saves lives,” the king said in the statement aired during a “Stand Up to Cancer” telethon on TV station Channel 4. He said catching the disease early had allowed him “to continue leading a full and active life even while undergoing treatment.”

Charles has received outpatient treatment for almost two years. Buckingham Palace did not say the king is in remission, but that his treatment is moving to a “precautionary phase” and his condition will be monitored to ensure his continued recovery.

“I know from my own experience that a cancer diagnosis can feel overwhelming,” the king said in his video statement. “Yet I also know that early detection is the key that can transform treatment journeys, giving invaluable time to medical teams – and, to their patients, the precious gift of hope.”

Charles announced in February 2024 that he had been diagnosed with cancer, and, in a break from centuries of secrecy about royal health, he has since spoken about the illness, using his story to promote cancer awareness and treatment.

The openness has limits, though. The king has not disclosed what type of cancer he has or what kind of treatment he is receiving. The palace said it was an intentional decision designed to ensure his message reaches the widest possible audience.

The king’s cancer was discovered after treatment for an enlarged prostate. While doctors ruled out prostate cancer, tests revealed “a separate issue of concern,” palace officials said last year.

Charles suspended his public appearances for about two months after his diagnosis. Since returning to the public eye, he has visited cancer treatment centers across the country and shared stories with fellow patients.

Buckingham Palace said Charles “will be greatly encouraged and deeply touched by the very positive reaction" his message has generated. “He will be particularly pleased at the way it has helped to shine a light on the benefits of cancer screening programs,” it added.

British cancer charities said the number of people seeking information about cancer jumped after the king revealed he was undergoing treatment last year.

Cancer Research U.K. said about 100,000 people have visited its Screening Checker website since it was launched on Dec. 5, most of them since the king’s statement on Friday.

The charity's Chief Executive Michelle Mitchell said: “When public figures speak openly about their cancer diagnosis, it can prompt others to check in on their health.”

Broadcaster Jonathan Dimbleby, the king’s authorized biographer, said the statement was “a remarkable thing for a monarch to do.”

“It takes guts, and the fact that he came out and did that will save lives,’” Dimbleby said.

The Princess of Wales, who announced her own cancer diagnosis six weeks after her father-in-law, has also given updates on her treatment. Kate announced in January that her cancer is in remission.

Find more of AP’s coverage at https://apnews.com/hub/royalty

Britain's King Charles III attends an Advent Service at Westminster Abbey, in London, Wednesday, Dec. 10, 2025. (Chris Jackson/Pool Photo via AP)

Britain's King Charles III attends an Advent Service at Westminster Abbey, in London, Wednesday, Dec. 10, 2025. (Chris Jackson/Pool Photo via AP)